Skip to main content
Article
Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
  • Ting Wang
  • Laura M. Fox
  • Desuo Wang, Philadelphia College of Osteopathic Medicine
Document Type
Article
Publication Date
1-1-2006
Abstract

MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound. © 2005 Elsevier B.V. All rights reserved.

Comments

This article was published in Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume 830, Issue 1, Pages 13-17.

The published version is available at http://dx.doi.org/10.1016/j.jchromb.2005.10.009.

Copyright © 2006 Scopus.

Citation Information
Ting Wang, Laura M. Fox and Desuo Wang. "Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma" Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences Vol. 830 Iss. 1 (2006) p. 13 - 17
Available at: http://works.bepress.com/desuo_wang/4/